

Barbara Ensoli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2655887/barbara-ensoli-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224
papers

12,474
citations

58
h-index

105
g-index

232
ext. papers

13,435
ext. citations

8
avg, IF

5.47
L-index

#	Paper	IF	Citations
224	Anti-Tat immunity defines CD4 T-cell dynamics in people living with HIV on long-term cART. <i>EBioMedicine</i> , 2021 , 66, 103306	8.8	3
223	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. <i>Archives of Virology</i> , 2021 , 166, 2955-2974	2.6	1
222	The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. <i>Vaccines</i> , 2020 , 8,	5.3	1
221	High HIV-1 diversity in immigrants resident in Italy (2008-2017). <i>Scientific Reports</i> , 2020 , 10, 3226	4.9	3
220	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020 , 19, 71-84	5.2	7
219	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	4
218	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2476-2489	6.1	2
217	Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. <i>Lancet HIV,the</i> , 2020 , 7, e772-e781	7.8	14
216	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. <i>Vaccines</i> , 2019 , 7,	5.3	9
215	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. <i>Frontiers in Immunology</i> , 2019 , 10, 233	8.4	12
214	Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, 143-155	25.5	135
213	The HIV-1 Tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of naïve CD4+ T cells. <i>Aids</i> , 2018 , 32, 575-581	3.5	11
212	The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	9
211	"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies". <i>Expert Review of Vaccines</i> , 2018 , 17, 115-126	5.2	4
210	Genetic diversity in the env V1-V2 region of proviral quasispecies from long-term controller MHC-typed cynomolgus macaques infected with SHIVSF162P4cy. <i>Journal of General Virology</i> , 2018 , 99, 1717-1728	4.9	1
209	Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. <i>Oncology Letters</i> , 2017 , 13, 2903-2908	2.6	8
208	Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study. <i>Medicine (United States)</i> , 2016 , 95, e5257	1.8	7

207	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. <i>Retrovirology</i> , 2016 , 13, 34	3.6	18
206	Approaches to preventative and therapeutic HIV vaccines. <i>Current Opinion in Virology</i> , 2016 , 17, 104-109	7.5	47
205	Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016. <i>Journal of AIDS & Clinical Research</i> , 2016 , 7,	1	4
204	Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. <i>BMC Infectious Diseases</i> , 2016 , 16, 344	4	11
203	HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. <i>BMC Infectious Diseases</i> , 2016 , 16, 442	4	6
202	Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. <i>Vaccine</i> , 2016 , 34, 2216-24	4.1	8
201	Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels. <i>Oncology Letters</i> , 2016 , 12, 2389-2394	3.6	16
200	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 1489-93	4.4	3
199	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15 Suppl 1, S13-29	5.4	13
198	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015 , 12, 33	3.6	36
197	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2015 , 51, 321-6	1.6	
196	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014 , 11, 49	3.6	32
195	The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells. <i>Angiogenesis</i> , 2014 , 17, 831-8	10.6	13
194	Effect of MHC haplotype on immune response upon experimental SHIVSF162P4cy infection of Mauritian cynomolgus macaques. <i>PLoS ONE</i> , 2014 , 9, e93235	3.7	10
193	Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms. <i>PLoS ONE</i> , 2014 , 9, e95183	3.7	3
192	Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 Tat β 1-59 protein in mice. <i>BioMed Research International</i> , 2014 , 2014, 904038	3	1
191	HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. <i>Aids</i> , 2014 , 28, 1729-38	3.5	28
190	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. <i>Aids</i> , 2014 , 28, 2189-200	3.5	12

189	Challenges in HIV Vaccine Research for Treatment and Prevention. <i>Frontiers in Immunology</i> , 2014 , 5, 4178-4		43
188	An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. <i>PLoS ONE</i> , 2014 , 9, e100844	3.7	12
187	Biocompatible anionic polymeric microspheres as priming delivery system for effective HIV/AIDS Tat-based vaccines. <i>PLoS ONE</i> , 2014 , 9, e111360	3.7	4
186	Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 1663-9	3.5	23
185	The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. <i>PLoS ONE</i> , 2013 , 8, e77746	3.7	30
184	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. <i>Journal of Immunological Methods</i> , 2012 , 375, 46-56	2.5	6
183	Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy. <i>Tissue Antigens</i> , 2012 , 80, 36-45		7
182	Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. <i>Aids</i> , 2012 , 26, 909-19	3.5	27
181	HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. <i>PLoS ONE</i> , 2012 , 7, e48781	3.7	40
180	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. <i>Vaccine</i> , 2011 , 29, 2918-32	4.1	19
179	Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. <i>Vaccine</i> , 2011 , 29, 6823-9	4.1	21
178	Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>International Journal of Vascular Medicine</i> , 2011 , 2011, 452729	1.2	11
177	Pharmacological management of Kaposi's sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1669-90		7
176	Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. <i>International Journal of Cancer</i> , 2011 , 128, 82-93	7.5	34
175	Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011 , 23, 939-46	2.2	9
174	Global trends in molecular epidemiology of HIV-1 during 2000-2007. <i>Aids</i> , 2011 , 25, 679-89	3.5	535
173	Spindle cells from AIDS-associated Kaposi's sarcoma lesions express telomerase activity that is enhanced by Kaposi's sarcoma progression factors. <i>Oncology Reports</i> , 2010 , 24, 219-23	3.5	3
172	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. <i>PLoS ONE</i> , 2010 , 5, e13540	3.7	73

171	Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. <i>Journal of Virology</i> , 2010 , 84, 8953-8	6.6	28
170	Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 705-9	1.6	9
169	Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland. <i>Journal of Clinical Virology</i> , 2010 , 48, 180-3	14.5	10
168	Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. <i>Atherosclerosis</i> , 2010 , 210, 400-6	3.1	11
167	Effect of the redox state on HIV-1 Tat protein multimerization and cell internalization and trafficking. <i>Molecular and Cellular Biochemistry</i> , 2010 , 345, 105-18	4.2	14
166	Spindle cells from acquired immune deficiency syndrome-associated Kaposi's sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2. <i>International Journal of Cancer</i> , 2010 , 127, 2487-9	7.5	1
165	HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. <i>International Reviews of Immunology</i> , 2009 , 28, 285-334	4.6	31
164	Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). <i>Viral Immunology</i> , 2009 , 22, 117-24	1.7	16
163	NKp44 expression, phylogenesis and function in non-human primate NK cells. <i>International Immunology</i> , 2009 , 21, 245-55	4.9	21
162	Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. <i>Journal of Immunology</i> , 2009 , 182, 3718-27	5.3	112
161	HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. <i>Journal of Immunology</i> , 2009 , 182, 2888-97	5.3	50
160	Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. <i>Journal of Gene Medicine</i> , 2009 , 11, 955-65	3.5	12
159	Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. <i>Advances in Experimental Medicine and Biology</i> , 2009 , 655, 189-242	3.6	13
158	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. <i>Vaccine</i> , 2009 , 27, 3306-12	4.1	39
157	Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. <i>Vaccine</i> , 2009 , 27, 3605-15	4.1	36
156	Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. <i>Vaccine</i> , 2009 , 27, 4498-507	4.1	9
155	The preventive phase I trial with the HIV-1 Tat-based vaccine. <i>Vaccine</i> , 2009 , 28, 371-8	4.1	39
154	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. <i>Aids</i> , 2009 , 23, 534-8	3.5	28

153	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. <i>Vaccine</i> , 2008 , 26, 727-37	4.1	47
152	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. <i>Vaccine</i> , 2008 , 26, 1214-27	4.1	17
151	Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. <i>Vaccine</i> , 2008 , 26, 5182-7	4.1	9
150	Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. <i>Vaccine</i> , 2008 , 26, 3312-21	4.1	38
149	Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 323-5	1.6	3
148	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. <i>Aids</i> , 2008 , 22, 2207-9	3.5	36
147	Primary effusion lymphoma cells undergoing human herpesvirus type 8 productive infection produce C-type retroviral particles. <i>International Journal of Immunopathology and Pharmacology</i> , 2008 , 21, 999-1006	3	4
146	IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. <i>Journal of Virology</i> , 2008 , 82, 3632-41	6.6	75
145	Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. <i>Current Drug Delivery</i> , 2008 , 5, 230-42	3.2	40
144	Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability. <i>Virus Genes</i> , 2008 , 36, 105-15	2.3	3
143	Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. <i>Archives of Virology</i> , 2008 , 153, 463-72	2.6	18
142	Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. <i>Journal of Medical Primatology</i> , 2007 , 36, 180-94	0.7	16
141	Control of human herpes virus type 8-associated diseases by NK cells. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1096, 37-43	6.5	8
140	Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. <i>Pharmaceutical Research</i> , 2007 , 24, 1870-82	4.5	33
139	Problems and emerging approaches in HIV/AIDS vaccine development. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 23-48	3.7	28
138	A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. <i>Journal of Virology</i> , 2007 , 81, 3414-27	6.6	76
137	Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. <i>Vaccine</i> , 2007 , 25, 6882-90	4.1	11
136	Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. <i>Seminars in Immunopathology</i> , 2006 , 28, 289-301		6

135	Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. <i>Journal of Cellular Physiology</i> , 2006 , 207, 107-13	7	30
134	Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 1335-6	10.3	
133	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. <i>Journal of General Virology</i> , 2006 , 87, 1625-1634	4.9	25
132	HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1985-94	3.5	61
131	Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. <i>Viral Immunology</i> , 2006 , 19, 690-701	1.7	34
130	Non-neutralizing antibodies and vaccine-induced protection. <i>Retrovirology</i> , 2006 , 3, S26	3.6	6
129	Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. <i>Vaccine</i> , 2006 , 24, 2049-56	4.1	46
128	DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. <i>Vaccine</i> , 2006 , 24, 5655-69	4.1	40
127	Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. <i>Vaccine</i> , 2006 , 24, 7148-58	4.1	12
126	Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. <i>Biochemical Journal</i> , 2006 , 396, 371-80	3.8	44
125	Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis. <i>FEMS Microbiology Letters</i> , 2006 , 262, 210-5	2.9	9
124	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. <i>Medical Science Monitor</i> , 2006 , 12, BR330-40	3.2	9
123	The use of HAART for biological tumour therapy. <i>Journal of HIV Therapy</i> , 2006 , 11, 53-6		6
122	Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2005 , 16, 1557-74	3.5	20
121	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. <i>Microbes and Infection</i> , 2005 , 7, 1392-9	9.3	16
120	Criteria for selection of HIV vaccine candidates--general principles. <i>Microbes and Infection</i> , 2005 , 7, 1433-53	5.3	10
119	Rational vaccine strategies against AIDS: background and rationale. <i>Microbes and Infection</i> , 2005 , 7, 1445-52	5.2	8
118	Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. <i>British Journal of Haematology</i> , 2005 , 130, 92-5	4.5	10

117	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. <i>Virology</i> , 2005 , 342, 1-12	3.6	22
116	Molecular and functional characterization of NKG2D, NKp80, and NKG2C triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function during simian HIV infection. <i>Journal of Immunology</i> , 2005 , 174, 5695-705	5.3	37
115	The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1321-4	7	96
114	Infection of a simian B cell line by human and simian immunodeficiency viruses. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 723-32	1.6	3
113	Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. <i>Journal of Virology</i> , 2004 , 78, 3333-42	6.6	46
112	Recent advances in the development of HIV-1 Tat-based vaccines. <i>Current HIV Research</i> , 2004 , 2, 357-76	1.3	37
111	HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. <i>Journal of Immunology</i> , 2004 , 173, 3838-43	5.3	83
110	Antitumour effects of antiretroviral therapy. <i>Nature Reviews Cancer</i> , 2004 , 4, 861-75	31.3	83
109	HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. <i>Cell Death and Differentiation</i> , 2004 , 11, 782-4	12.7	12
108	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. <i>Journal of Immunological Methods</i> , 2004 , 291, 153-63	2.5	6
107	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004 , 324, 531-9	3.6	12
106	Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1030, 187-95	6.5	9
105	Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. <i>Current Opinion in Biotechnology</i> , 2004 , 15, 543-56	11.4	29
104	Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. <i>Vaccine</i> , 2004 , 22, 2910-24	4.1	36
103	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004 , 22, 3258-69	4.1	60
102	On the role of interferon regulatory factors in HIV-1 replication. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1010, 29-42	6.5	13
101	Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. <i>European Journal of Immunology</i> , 2003 , 33, 1548-56	6.1	60
100	HIV protease inhibitors as new treatment options for Kaposi's sarcoma. <i>Drug Resistance Updates</i> , 2003 , 6, 173-81	23.2	10

99	Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. <i>Vaccine</i> , 2003 , 21, 1103-11	4.1	25
98	Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. <i>Vaccine</i> , 2003 , 21, 2073-81	4.1	35
97	Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. <i>Vaccine</i> , 2003 , 21, 3972-81	4.1	25
96	Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. <i>Lancet Oncology</i> , 2003 , 4, 537-47	21.7	111
95	CD8(+)CD28(-) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. <i>Journal of Interferon and Cytokine Research</i> , 2003 , 23, 523-31	3.5	9
94	Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1171-80	7	60
93	Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB Journal</i> , 2003 , 17, 461-3	0.9	27
92	HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 207-11	5.1	23
91	NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. <i>European Journal of Immunology</i> , 2002 , 32, 2711-20	6.1	77
90	The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. <i>European Journal of Immunology</i> , 2002 , 32, 2857-65	6.1	106
89	Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. <i>Immunology</i> , 2002 , 106, 395-403	4.3	43
88	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. <i>Nature Medicine</i> , 2002 , 8, 225-32	50.5	269
87	HIV-1 Tat-based vaccines: from basic science to clinical trials. <i>DNA and Cell Biology</i> , 2002 , 21, 599-610	3.6	32
86	IRF regulation of HIV-1 long terminal repeat activity. <i>Journal of Interferon and Cytokine Research</i> , 2002 , 22, 27-37	3.5	36
85	Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 4652-8	9.7	43
84	Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. <i>Journal of Experimental Medicine</i> , 2002 , 195, 1359-70	16.6	82
83	Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. <i>Clinical Microbiology Reviews</i> , 2002 , 15, 310-26	34	96
82	Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. <i>Journal of Immunology</i> , 2002 , 168, 197-206	5.3	139

81	Treatment of Kaposi's sarcoma--an update. <i>Anti-Cancer Drugs</i> , 2002 , 13, 977-87	2.4	20
80	Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. <i>American Journal of Pathology</i> , 2002 , 161, 1749-59	5.8	112
79	Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. <i>Vaccine</i> , 2002 , 20, 2303-17	4.1	24
78	HIV-1 Tat vaccines. <i>Virus Research</i> , 2002 , 82, 91-101	6.4	15
77	Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. <i>Advances in Cancer Research</i> , 2001 , 81, 125-59	5.9	59
76	Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. <i>Advances in Cancer Research</i> , 2001 , 81, 161-200	5.9	61
75	Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. <i>Journal of Medical Primatology</i> , 2001 , 30, 207-14	0.7	33
74	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Multicentre study with multiple and novel assays. <i>Journal of Medical Virology</i> , 2001 , 65, 123-132	19.7	50
73	Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in <i>Macaca fascicularis</i> NK cells. <i>European Journal of Immunology</i> , 2001 , 31, 3546-56	6.1	56
72	A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. <i>European Journal of Epidemiology</i> , 2001 , 17, 871-6	12.1	42
71	Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients. <i>Journal of Infection</i> , 2001 , 43, 195-9	18.9	84
70	The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. <i>EMBO Journal</i> , 2001 , 20, 5568-77	13	144
69	Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. <i>Molecular Biology of the Cell</i> , 2001 , 12, 2934-46	3.5	104
68	Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma. <i>Journal of Virology</i> , 2001 , 75, 7161-74	6.6	31
67	Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1782-5	11.6	7
66	Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 1035-9	1.6	20
65	Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function. <i>Atherosclerosis</i> , 2001 , 154, 377-85	3.1	65
64	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001 , 19, 2862-77	4.1	120

63	Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. <i>Vaccine</i> , 2001 , 19, 3408-19	4.1	14
62	Interactions between endothelial cells and HIV-1. <i>International Journal of Biochemistry and Cell Biology</i> , 2001 , 33, 371-90	5.6	53
61	Biology of Kaposi's sarcoma. <i>European Journal of Cancer</i> , 2001 , 37, 1251-69	7.5	206
60	NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*. <i>Clinical Research and Regulatory Affairs</i> , 2001 , 18, 293-327		1
59	Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2001 , 12, 209-28	3.5	16
58	Human herpesvirus-8 and other viral infections, Papua New Guinea. <i>Emerging Infectious Diseases</i> , 2001 , 7, 893-5	10.2	20
57	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Multicentre study with multiple and novel assays 2001 , 65, 123		3
56	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2000 , 29, 193-208	0.7	42
55	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study. <i>Aids</i> , 2000 , 14, 1647-53	3.5	24
54	Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. <i>Seminars in Cancer Biology</i> , 2000 , 10, 367-81	12.7	63
53	Limited expression of R5-tropic HIV-1 in CCR5-positive type 1 polarized T cells explained by their ability to produce RANTES, MIP-1 β and MIP-1 α <i>Blood</i> , 2000 , 95, 1167-1174	2.2	46
52	Lytic growth of human herpesvirus 8: morphological aspects. <i>Ultrastructural Pathology</i> , 2000 , 24, 301-10	1.3	5
51	Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. <i>Sexually Transmitted Diseases</i> , 2000 , 27, 159-64	2.4	43
50	CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses. <i>Journal of Virology</i> , 2000 , 74, 6689-94	6.6	17
49	Mechanism of paclitaxel activity in Kaposi's sarcoma. <i>Journal of Immunology</i> , 2000 , 165, 509-17	5.3	67
48	High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 465-9	9.7	121
47	Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1725-33	9.7	149
46	Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1468-74	8.7	117

45	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999 , 5, 643-50	50.5	259
44	Human herpesvirus-8 (HHV-8) gene expression in KaposiB sarcoma (KS) primary lesions: an in situ hybridization study. <i>Leukemia</i> , 1999 , 13 Suppl 1, S110-2	10.7	30
43	HHV-8 and multistep tumorigenesis. <i>Trends in Microbiology</i> , 1999 , 7, 310-2	12.4	6
42	Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in KaposiB sarcoma (KS) primary lesions. <i>Advances in Enzyme Regulation</i> , 1999 , 39, 331-9		15
41	Variability and evolution of KaposiB sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. <i>Aids</i> , 1999 , 13, 1165-76	3.5	89
40	Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. <i>Journal of Virology</i> , 1999 , 73, 4029-41	6.6	64
39	Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. <i>International Journal of Cancer</i> , 1998 , 77, 361-5	7.5	77
38	Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms. <i>Neuroscience</i> , 1998 , 86, 881-93	3.9	30
37	KaposiB sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. <i>Cytokine and Growth Factor Reviews</i> , 1998 , 9, 63-83	17.9	156
36	Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of KaposiB sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. <i>Aids</i> , 1998 , 12, 19-27	3.5	60
35	Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of KaposiB sarcoma. <i>Current Opinion in Infectious Diseases</i> , 1998 , 11, 97-105	5.4	20
34	Purified Tat induces inflammatory response genes in KaposiB sarcoma cells. <i>Aids</i> , 1998 , 12, 1753-61	3.5	24
33	Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From KaposiB Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. <i>Blood</i> , 1998 , 91, 968-976	2.2	99
32	Interferon Production in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes From KaposiB Sarcoma Patients: Correlation With the Presence of Human Herpesvirus-8 in Peripheral Blood Mononuclear Cells and Lesional Macrophages. <i>Blood</i> , 1998 , 91, 968-976	2.2	3
31	KaposiB sarcoma pathogenesis: a link between immunology and tumor biology. <i>Critical Reviews in Oncogenesis</i> , 1998 , 9, 107-24	1.3	39
30	HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. <i>Aids</i> , 1997 , 11, 1421-31	3.5	352
29	Circulating spindle cells: correlation with human herpesvirus-8 (HHV-8) infection and KaposiB sarcoma. <i>Lancet, The</i> , 1997 , 349, 255	40	40
28	Differential activation of the extracellular signal-regulated kinase, Jun kinase and Janus kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived KaposiB sarcoma cells. <i>Aids</i> , 1996 , 10, 369-78	3.5	33

27	Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys. <i>Virology</i> , 1996 , 222, 252-6	3.6	13
26	Efficacy of antitart gene therapy in the presence of high multiplicity infection and inflammatory cytokines. <i>Human Gene Therapy</i> , 1996 , 7, 2209-16	4.8	5
25	Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein. <i>Journal of Biomedical Science</i> , 1995 , 2, 189-202	13.3	75
24	HIV-1 infection of primary human neuroblasts. <i>Virology</i> , 1995 , 210, 221-5	3.6	39
23	Angiogenic properties of human immunodeficiency virus type 1 Tat protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 4838-42	11.5	191
22	Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-KaposiB sarcoma spindle cells. <i>Journal of Clinical Investigation</i> , 1995 , 95, 1723-34	15.9	127
21	KaposiB sarcoma, vascular permeability, and scientific integrity. <i>JAMA - Journal of the American Medical Association</i> , 1994 , 272, 918-9; author reply 922-4	27.4	
20	HIV-1 gene expression and replication in neuronal and glial cell lines with immature phenotype: effects of nerve growth factor. <i>Virology</i> , 1994 , 200, 668-76	3.6	27
19	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of KaposiB sarcoma. <i>Nature</i> , 1994 , 371, 674-80	50.4	517
18	Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. <i>Human Gene Therapy</i> , 1994 , 5, 1467-75	4.8	32
17	Block of AIDS-KaposiB sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. <i>Journal of Clinical Investigation</i> , 1994 , 94, 1736-46	15.9	113
16	The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 7344-8	11.5	303
15	Cytokines and growth factors in the pathogenesis of AIDS-associated KaposiB sarcoma. <i>Immunological Reviews</i> , 1992 , 127, 147-55	11.3	132
14	Pathogenesis of AIDS-Associated KaposiB Sarcoma. <i>Hematology/Oncology Clinics of North America</i> , 1991 , 5, 281-295	3.1	77
13	Molecular mechanisms in the pathogenesis of AIDS-associated KaposiB sarcoma. <i>Advances in Experimental Medicine and Biology</i> , 1991 , 303, 27-38	3.6	21
12	Tat protein of HIV-1 stimulates growth of cells derived from KaposiB sarcoma lesions of AIDS patients. <i>Nature</i> , 1990 , 345, 84-6	50.4	817
11	KaposiB sarcoma and AIDS. <i>Nature</i> , 1990 , 346, 801-802	50.4	2
10	In Reply: Pseudotypes in HIV-Infected Mice. <i>Science</i> , 1990 , 250, 1153-4	33.3	1

9	Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. <i>Science</i> , 1990 , 247, 848-52	33.3	140
8	AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. <i>Science</i> , 1989 , 243, 223-6	33.3	415
7	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. <i>Nature</i> , 1989 , 337, 370-3	50.4	286
6	Biologically diverse molecular variants within a single HIV-1 isolate. <i>Nature</i> , 1988 , 334, 444-7	50.4	248
5	Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. <i>Science</i> , 1988 , 242, 426-30	33.3	322
4	The <i>src</i> gene of HIV-1 is required for efficient virus transmission in vitro. <i>Science</i> , 1987 , 237, 888-93	33.3	323
3	Clinical and immunological findings in four infants with Omenn's syndrome: a form of severe combined immunodeficiency with phenotypically normal T cells, elevated IgE, and eosinophilia. <i>Clinical Immunology and Immunopathology</i> , 1987 , 44, 123-33		28
2	New human and simian HIV-related retroviruses possess functional transactivator (<i>tat</i>) gene. <i>Nature</i> , 1987 , 328, 548-50	50.4	83
1	Results in two infants with the DiGeorge syndrome--effects of long-term TP5. <i>Clinical Immunology and Immunopathology</i> , 1986 , 39, 222-30		5